GlassScriptPhysician profile
Arturo E Marchand
NPI 1811077670
$16,214.89
in general payments reported to CMS, 2019-2025
41 companies · $3,387 in 2025
The $3,387 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,497 · 2020: $1,353 · 2021: $2,731 · 2022: $1,166 · 2023: $2,742 · 2024: $2,339 · 2025: $3,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,164 · Travel and Lodging: $284 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,164.36 |
| Travel and Lodging | $284.29 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,741.52 | 2019-2025 | Crossboss, General - Therapies, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $1,821.36 | 2019-2025 | |
| Abiomed | $1,441.00 | 2019-2025 | Impella |
| Abbott Laboratories | $1,055.90 | 2019-2025 | Aveir, Mitraclip, Cardiomems |
| Amgen INC. | $1,021.73 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $885.34 | 2019-2024 | Xarelto |
| Medtronic, INC. | $806.44 | 2024-2025 | Onyx Frontier, Symplicity G3, Venaseal |
| Cvrx, INC. | $777.76 | 2021-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $773.49 | 2021-2025 | Verquvo, Capvaxive, Steglatro |
| Asahi Intecc USA, INC. | $524.06 | 2021-2025 | Asahi Peripheral Vascular Wires |
| E.R. Squibb & Sons, L.L.C. | $523.58 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $376.81 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.09 | 2019-2025 | Jardiance |
| Medtronic Vascular, INC. | $319.68 | 2019-2020 | |
| Pfizer INC. | $302.42 | 2022-2023 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $232.26 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $229.92 | 2023-2024 | Inpefa |
| Bridgebio Pharma, INC. | $203.55 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $191.20 | 2019-2024 | |
| Shockwave Medical, INC | $184.57 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $163.51 | 2019-2022 | |
| Acist Medical Systems, INC. | $151.25 | 2019 | |
| Teleflex LLC | $149.86 | 2022 | |
| W. L. Gore & Associates, INC. | $149.29 | 2023 | Gore Cardioform Septal Occluder |
| Penumbra, INC. | $139.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.29 | 2023-2025 | |
| Tactile Systems Technology INC | $82.70 | 2020-2023 | Entre Plus, Flexitouch Plus |
| Novo Nordisk INC | $75.95 | 2021-2022 | |
| Esperion Therapeutics, INC. | $62.75 | 2020-2025 | Nexletol |
| Impulse Dynamics (USA) INC. | $52.38 | 2022 | |
| Cleerly, INC. | $49.55 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Edwards Lifesciences Corporation | $40.09 | 2025 | |
| Becton, Dickinson and Company | $38.55 | 2020 | |
| Cardiovascular Systems INC. | $34.89 | 2019-2021 | |
| Daiichi Sankyo INC. | $23.22 | 2023 | Injectafer |
| Corcept Therapeutics | $18.54 | 2022 | |
| Currax Pharmaceuticals LLC | $17.06 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $16.31 | 2019 | |
| Koya Medical, INC. | $15.74 | 2025 | Dayspring, Koya Medical |
| Amarin Pharma, INC. | $15.10 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arturo Marchand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.